Patrick Hwu: How can we enhance CAR-T cell activity against solid cancers?
Patrick Hwu, President and CEO of Moffitt Cancer Center, shared a post on X:
“How can we enhance CAR-T cell activity against solid cancers?
In a recent study, Zhao et al transduced CAR-T to express IL-10, resulting in enhanced T-cell proliferation, effector function, mitochondrial capacity and antitumor activity in a variety of solid tumor murine models.
This exciting approach holds promise for patients with solid malignancies.
Here’s a link to the full article.”
Authors: Yang Zhao, Jiangqing Chen, Massimo Andreatta, Bing Feng, Yu-Qing Xie, Mathias Wenes, Yi Wang, Min Gao, Xiaomeng Hu, Pedro Romero, Santiago Carmona, Jie Sun, Yugang Guo, Li Tang
More posts featuring Patrick Hwu.
Dr. Patrick Hwu, MD, currently serves as the President and CEO of Moffitt Cancer Center. With a focus on understanding the dynamics between tumors and the immune system, Dr. Hwu’s research has been pivotal in advancing gene-modified T cell therapy. He notably contributed seminal work on the development of the first chimeric antigen receptor aimed at combating cancer.
His research portfolio extends to vaccines, adoptive T-cell therapies, and mechanisms of immune resistance. Before joining, Dr. Hwu held numerous leadership roles at The University of Texas MD Anderson Cancer Center for over 17 years.
Notably, he served as the inaugural Chairman of the Department of Melanoma Medical Oncology in 2003, as well as the Associate Director of the Center for Cancer Immunology Research. Additionally, he chaired the Department of Sarcoma Medical Oncology, demonstrating his commitment to advancing cancer treatment and research.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023